UFP TECHNOLOGIES Business Summary

UFP Technologies Inc. (UFPT) operates as a high-precision Contract Development and Manufacturing Organization (CDMO) primarily serving the medical technology (MedTech) sector, which accounts for over 90% of its total revenue. The company generates revenue through the custom engineering and manufacturing of single-use medical devices, sterile packaging, and complex subassemblies utilizing specialized foams, films, and plastics. Its business model is built on deep vertical integration and long-term supply agreements with 26 of the world's top 30 medical device OEMs, focusing on high-growth niches such as robotic-assisted surgery, interventional cardiology, and orthopedic implants. While it maintains secondary segments in Aerospace & Defense and Automotive, UFPT has pivoted decisively toward regulated, high-margin healthcare solutions. Direct competitors include Technimark LLC, Oliver Healthcare Packaging, DeRoyal Industries, and Röchling Medical; UFPT distinguishes itself as a specialized, engineering-led partner that bridges the gap between material science and regulatory-compliant manufacturing. Leadership is currently spearheaded by R. Jeffrey Bailly, who has served as Chairman and CEO for 31 years and is credited with transforming the 1963-founded company into a global MedTech leader before his scheduled transition to Executive Chairman in June 2026. He is supported by President and CEO-elect Mitchell Rock, a 25-year company veteran with deep expertise in customer relations and strategic market expansion, and Ronald J. Lataille, who serves as Senior Vice President, CFO, and Treasurer. The executive team is complemented by a majority-independent Board of Directors, including Lead Director Daniel Croteau and Cynthia Feldmann, a veteran of the Steris PLC board. The company's ownership structure is predominantly institutional, with major stakeholders including prominent small-cap and healthcare-focused mutual funds that hold over 50% of the free float, reflecting strong market confidence in the firm's acquisition-led growth strategy.